OrthoPediatrics (NASDAQ:KIDS) Shares Down 3.7% – What’s Next?

Posted by George Bondi on Aug 23rd, 2026

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS – Get Free Report) were down 3.7% during mid-day trading on Friday . The company traded as low as $25.23 and last traded at $25.25. 104,364 shares changed hands during mid-day trading, a decline of 38% from the average session volume of 168,822 shares. The stock had previously closed at $26.23.

Wall Street Analyst Weigh In

Several research firms have issued reports on KIDS. Needham & Company LLC raised their target price on OrthoPediatrics from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. BTIG Research increased their price objective on shares of OrthoPediatrics from $24.00 to $29.00 and gave the stock a “buy” rating in a research report on Thursday. TD Cowen reiterated a “buy” rating on shares of OrthoPediatrics in a report on Monday, June 15th. Truist Financial set a $22.00 price target on OrthoPediatrics in a research note on Wednesday, August 5th. Finally, Weiss Ratings raised OrthoPediatrics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 5th. Nine equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $26.44.

Check Out Our Latest Report on KIDS

OrthoPediatrics Stock Performance

The stock has a 50-day moving average price of $20.85 and a 200 day moving average price of $18.41. The company has a quick ratio of 2.17, a current ratio of 4.78 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $669.72 million, a price-to-earnings ratio of -15.27 and a beta of 0.98.

OrthoPediatrics (NASDAQ:KIDS – Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.04. OrthoPediatrics had a negative net margin of 15.72% and a negative return on equity of 8.10%. The firm had revenue of $70.51 million for the quarter, compared to analysts’ expectations of $68.21 million. On average, analysts forecast that OrthoPediatrics Corp. will post -1.14 EPS for the current year.

Hedge Funds Weigh In On OrthoPediatrics

Large investors have recently bought and sold shares of the business. Millennium Management LLC raised its stake in OrthoPediatrics by 48.0% in the fourth quarter. Millennium Management LLC now owns 1,396,495 shares of the company’s stock valued at $24,802,000 after buying an additional 452,840 shares in the last quarter. BlackRock Inc. acquired a new position in shares of OrthoPediatrics during the 2nd quarter worth about $24,347,000. Vanguard Group Inc. increased its holdings in shares of OrthoPediatrics by 1.1% in the 3rd quarter. Vanguard Group Inc. now owns 961,330 shares of the company’s stock valued at $17,813,000 after acquiring an additional 10,927 shares during the last quarter. Granahan Investment Management LLC increased its holdings in shares of OrthoPediatrics by 35.1% in the 1st quarter. Granahan Investment Management LLC now owns 896,741 shares of the company’s stock valued at $14,231,000 after acquiring an additional 232,760 shares during the last quarter. Finally, Wasatch Advisors LP raised its position in shares of OrthoPediatrics by 56.6% during the 2nd quarter. Wasatch Advisors LP now owns 515,677 shares of the company’s stock worth $9,865,000 after acquiring an additional 186,357 shares in the last quarter. Hedge funds and other institutional investors own 69.05% of the company’s stock.

OrthoPediatrics Company Profile

(Get Free Report)

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.